H.R. 7980: Protecting Americans from Unsafe Drugs Act of 2026

This bill, known as the Protecting Americans from Unsafe Drugs Act of 2026, proposes amendments to existing laws concerning the recall and regulation of drugs. The key features of the bill include:

1. Expanded Definition of Drugs

The bill modifies the definitions related to the recall of drugs in the Federal Food, Drug, and Cosmetic Act. Specifically, it replaces references to “controlled substances” with the term “drugs,” thereby expanding the scope of the law to cover all drugs, not just controlled substances. This means that the regulatory framework for recalling drugs will apply more broadly.

2. Authority to Recall Drugs

The bill provides the authority for drug officials to issue a **cease distribution and recall** order for any drugs that may pose a risk to public health. This is similar to existing provisions for controlled substances but will now encompass all drugs.

3. Notification and Compliance Processes

The amendment also outlines the processes for notifying relevant parties in the case of a recall, ensuring that manufacturers and distributors comply with these orders more effectively.

4. Imports and Exports of Drugs

In addition to recalls, the bill adjusts the regulations surrounding the import and export of drugs. Previous language referring to “controlled substances” will be updated to reflect the broader categorization of “drugs,” thus influencing how imported and exported products are regulated regarding recall orders.

5. Strengthening Regulatory Oversight

By expanding the regulations to all drugs, this legislation aims to strengthen the ability of health authorities to act quickly and decisively in response to safety concerns, thus enhancing overall public safety regarding pharmaceuticals.

6. Impact on Drug Regulation Authorities

The amendments would enhance the roles and responsibilities of the Director of the Center for Biologics Evaluation and Research and other relevant officials. This change is intended to increase accountability and ensure swift action during drug recalls.

7. Overall Goals

The main objective of the Protecting Americans from Unsafe Drugs Act of 2026 is to provide a more comprehensive safety net for drug regulation, intending to protect public health by ensuring that potentially harmful drugs can be recalled safely and efficiently.

Relevant Companies

• PFE - Pfizer Inc.: Likely to be impacted due to their wide range of drug products that may be subject to expanded recall authority.
• MRK - Merck & Co., Inc.: As a major pharmaceutical company, they may need to adapt to new regulations regarding drug recalls.
• JNJ - Johnson & Johnson: With various drug products, they may face increased regulatory scrutiny under the broader definitions established by this bill.